Abstract: One aspect of the present application relates to a storage stable pharmaceutical composition comprising a sulfated glycosaminoglycan having an average molecular weight ranging from 3,000 to 15,000 Daltons, and a pharmaceutical carrier, where the pharmaceutical carrier is mixed with the sulfated glycosaminoglycan, as well as this composition's use in a method of treating a subject for a medically observable improvement. Another aspect of the present application relates to a process for producing a storage stable purified sulfated glycosaminoglycan.

Abstract: One aspect of the present application relates to a storage stable pharmaceutical composition comprising a sulfated glycosaminoglycan having an average molecular weight ranging from 3,000 to 15,000 Daltons, and a pharmaceutical carrier, where the pharmaceutical carrier is mixed with the sulfated glycosaminoglycan, as well as this composition's use in a method of treating a subject for a medically observable improvement. Another aspect of the present application relates to a process for producing a storage stable purified sulfated glycosaminoglycan.

Abstract: One aspect of the present application relates to a storage stable pharmaceutical composition comprising a sulfated glycosaminoglycan having an average molecular weight ranging from 3,000 to 15,000 Daltons, and a pharmaceutical carrier, where the pharmaceutical carrier is mixed with the sulfated glycosaminoglycan, as well as this composition's use in a method of treating a subject for a medically observable improvement. Another aspect of the present application relates to a process for producing a storage stable purified sulfated glycosaminoglycan.

Abstract: The present invention concerns pharmaceutical formulations of ARN-509, which can be administered to a mammal, in particular a human, suffering from an androgen receptor (AR)-related disease or condition, in particular cancer, more in particular prostate cancer, including but not limited to castration-resistant prostate cancer, metastatic castration resistant prostate cancer, chemotherapy-naive metastatic castration resistant prostate cancer, biochemically relapsed hormone sensitive prostate cancer, or high-risk, non-metastatic castration-resistant prostate cancer. In one aspect, these formulations comprise a solid dispersion of ARN-509 and HPMCAS. In one aspect, the solid dispersion of ARN-509 and HPMCAS is obtainable, in particular is obtained, by melt-extruding a mixture comprising ARN-509 and HPMCAS and optionally subsequently milling said melt-extruded mixture.

Abstract: One aspect of the present application relates to a storage stable pharmaceutical composition comprising a sulfated glycosaminoglycan having an average molecular weight ranging from 3,000 to 15,000 Daltons, and a pharmaceutical carrier, where the pharmaceutical carrier is mixed with the sulfated glycosaminoglycan, as well as this composition's use in a method of treating a subject for a medically observable improvement. Another aspect of the present application relates to a process for producing a storage stable purified sulfated glycosaminoglycan.

Abstract: One aspect of the present application relates to a pharmaceutical composition comprising a sulfated glycosaminoglycan having an average molecular weight ranging from 3,000 to 15,000 Daltons, a skin penetrating agent, where the skin penetrating agent promotes transdermal penetration of the sulfated glycosaminoglycan when applied to intact skin surfaces, and a pharmaceutical carrier for topical application, where the pharmaceutical carrier is mixed with the sulfated glycosaminoglycan and the skin penetrating agent. This composition is useful in carrying out a method of treating a subject for pain, joint stiffness, soft tissue injury, connective tissue disorders, and/or muscle soreness.

Abstract: Described herein are pharmaceutical compositions comprising one or more fumarate esters and methods for treating multiple sclerosis subjects with the compositions where the incidence of gastrointestinal side effects is reduced compared to treatments comprising dimethyl fumarate (e.g., TECFIDERA®). In particular, described herein are oral pharmaceutical compositions comprising monomethyl fumarate in a liquid vehicle that have reduced gastrointestinal side effects.

Abstract: Mower blades are provided having a hexagonal central aperture configured such that a variety of retaining plates can pass through the aperture. This allows the mower blade to function with replaceable-blade mower systems having any of a variety of retaining-plate shapes, including both symmetric and asymmetric retaining-plate shapes, including S-shaped retaining plates.

Abstract: The present invention concerns pharmaceutical formulations of ARN-509, which can be administered to a mammal, in particular a human, suffering from an androgen receptor (AR)-related disease or condition, in particular cancer, more in particular prostate cancer, including but not limited to castration-resistant prostate cancer, metastatic castration resistant prostate cancer, chemotherapy-naïve metastatic castration resistant prostate cancer, biochemically relapsed hormone sensitive prostate cancer, or high-risk, non-metastatic castration-resistant prostate cancer. In one aspect, these formulations comprise a solid dispersion of ARN-509 and HPMCAS. In one aspect, the solid dispersion of ARN-509 and HPMCAS is obtainable, in particular is obtained, by melt-extruding a mixture comprising ARN-509 and HPMCAS and optionally subsequently milling said melt-extruded mixture.

Abstract: Described herein are pharmaceutical compositions comprising one or more fumarate esters and methods for treating multiple sclerosis subjects with the compositions where the incidence of gastrointestinal side effects is reduced compared to treatments comprising dimethyl fumarate (e.g., TECFIDERA®). In particular, described herein are oral pharmaceutical compositions comprising monomethyl fumarate in a liquid vehicle that have reduced gastrointestinal side effects.

Abstract: The present invention provides a goalie blocking glove that features a non-binding front blocking board surface that incorporates a carbon fiber front layer over the ultra-high density internal foam core, for lighter weight and added protection under extreme impacts. An adjustment mechanism is also included in the blocker glove, to allow the goalie to customize the fit of the inner glove to his or her individual hand size.

Abstract: A marking stylus for use in automated marking systems with one of the following superabrasive components as the scribing tip: polycrystalline diamond or polycrystalline cubic boron nitride. The superabrasive may have one or more chamfers, as well as a sharp, rounded, or blunt tip. The superabrasive is preferably attached to the body of the stylus by one of the following methods: brazing, press fit, shrunk fit, clamped, casted, injection molded, or a high pressure high temperature cycle.

Abstract: The present invention is directed to systems and methods for objectively assessing mission readiness. The systems can comprise a backend system and scenario server in communication with the backend system. The backend system can comprise a planning and analysis system comprising planning and/or assessing data for one or more training missions, a common database builder comprising geographical data of a geographical region for the training mission, and a digital media replicator comprising a social media module configured to receive publically accessible data relevant to the training mission from one or more social media platforms. The scenario server is configured to receive data from each of the planning and analysis system, common database builder, and digital media replication to create the training mission. Methods in accordance with such systems are disclosed herein.

Abstract: The present invention is directed to systems and methods for objectively assessing mission readiness. The systems can comprise a backend system and scenario server in communication with the backend system. The backend system can comprise a planning and analysis system comprising planning and/or assessing data for one or more training missions, a common database builder comprising geographical data of a geographical region for the training mission, and a digital media replicator comprising a social media module configured to receive publically accessible data relevant to the training mission from one or more social media platforms. The scenario server is configured to receive data from each of the planning and analysis system, common database builder, and digital media replication to create the training mission. Methods in accordance with such systems are disclosed herein.

Abstract: A marking stylus for use in automated marking systems with one of the following superabrasive components as the scribing tip: polycrystalline diamond or polycrystalline cubic boron nitride. The superabrasive may have one or more chamfers, as well as a sharp, rounded, or blunt tip. The superabrasive is preferably attached to the body of the stylus by one of the following methods: brazing, press fit, shrunk fit, clamped, casted, injection molded, or a high pressure high temperature cycle.

Abstract: A vacuum cup assembly that generates a local vacuum using a prime mover that may be an electrical motor or a solenoid. The vacuum cup may have one or more ports to remove and vent air between the cup and the atmosphere. The prime mover drives a piston or a flexible membrane, which may be a diaphragm, through one or more reciprocating cycles to generate the local vacuum. The vacuum cup assembly may be used to form a temporary attachment to a work piece, the act on the work piece, such as by moving the work piece, and then release the work piece from the vacuum cup assembly. The vacuum cup assembly disclosed herein is self-contained inasmuch as the assembly may have a power source, such as a battery, located on a housing. This makes its operation quiet and effective.

Abstract: A vacuum cup assembly that generates a local vacuum using a prime mover that may be an electrical motor or a solenoid. The vacuum cup may have one or more ports to remove and vent air between the cup and the atmosphere. The prime mover drives a piston or a flexible membrane, which may be a diaphragm, through one or more reciprocating cycles to generate the local vacuum. The vacuum cup assembly may be used to form a temporary attachment to a work piece, the act on the work piece, such as by moving the work piece, and then release the work piece from the vacuum cup assembly. The vacuum cup assembly disclosed herein is self-contained inasmuch as the assembly may have a power source, such as a battery, located on a housing. This makes its operation quiet and effective.

Abstract: The present invention concerns pharmaceutical formulations of ARN-509, which can be administered to a mammal, in particular a human, suffering from an androgen receptor (AR)-related disease or condition, in particular cancer, more in particular prostate cancer, including but not limited to castration-resistant prostate cancer, metastatic castration resistant prostate cancer, chemotherapy-naive metastatic castration resistant prostate cancer, biochemically relapsed hormone sensitive prostate cancer, or high-risk, non-metastatic castration-resistant prostate cancer. In one aspect, these formulations comprise a solid dispersion of ARN-509 and HPMCAS. In one aspect, the solid dispersion of ARN-509 and HPMCAS is obtainable, in particular is obtained, by melt-extruding a mixture comprising ARN-509 and HPMCAS and optionally subsequently milling said melt-extruded mixture.

Abstract: A vacuum cup assembly that generates a local vacuum using a prime mover that may be an electrical motor or a solenoid. The vacuum cup may have one or more ports to remove and vent air between the cup and the atmosphere. The prime mover drives a piston or a flexible membrane, which may be a diaphragm, through one or more reciprocating cycles to generate the local vacuum. The vacuum cup assembly may be used to form a temporary attachment to a work piece, the act on the work piece, such as by moving the work piece, and then release the work piece from the vacuum cup assembly. The vacuum cup assembly disclosed herein is self-contained inasmuch as the assembly may have a power source, such as a battery, located on a housing. This makes its operation quiet and effective.

Abstract: A pipeline pig signal includes sealing means located within a lower end of the trigger cavity of the signal which prevents pipeline debris from entering the trigger cavity. The sealing means moves between a first sealing position and a second sealing position in response to the trigger moving between a non-triggered and triggered position. The sealing means may be a polymer boot, a filter arrangement, a sliding piston arrangement, or a sliding shelf arrangement.